Online Table 1. Length of stay in matched cohorts of patients with VAP and patients without VAPa
MS-DRG Population (Code) Outcome Type
Mean Duration (days) ± SDb P With VAP Without VAP ECMO or tracheostomy with mechanical ventilation ≥96 hours or
principal diagnosis except face, mouth, and neck with major OR (3)
n = 587 n = 587
Mechanical ventilation 30.6 ± 27.3 25.5 ± 20.2 <.001
ICU 29.7 ± 18.2 27.9 ± 20.9 .115
Hospital 46.0 ± 33.5 44.1 ± 42.2 .399
Tracheostomy with mechanical ventilation ≥96 hours or principal diagnosis except face, mouth, and neck without major OR (4)
n = 222 n = 222
Mechanical ventilation 30.8 ± 26.0 22.2 ± 12.6 <.001
ICU 26.2 ± 15.8 21.8 ± 11.6 <.001
Hospital 42.1 ± 41.7 30.5 ± 16.7 <.001
Respiratory system diagnosis with ventilator support ≥96 hours (207) n = 226 n = 226
Mechanical ventilation 14.2 ± 11.0 10.5 ± 9.5 <.001
ICU 12.7 ± 11.5 10.2 ± 5.5 .004
Hospital 18.6 ± 19.6 16.0 ± 10.8 .083
Septicemia or severe sepsis with mechanical ventilation ≥96 hours (870) n = 157 n = 157
Mechanical ventilation 17.4 ± 17.8 9.4 ± 4.5 <.001
ICU 15.0 ± 12.1 11.0 ± 5.6 <.001
Hospital 22.6 ± 25.6 16.0 ± 9.3 .003
Infectious and parasitic diseases with OR with major complication or
comorbidity (853) n = 46 n = 46
Mechanical ventilation 30.0 ± 48.7 8.8 ± 5.6 .004
ICU 17.6 ± 16.8 12.3 ± 7.6 .053
Hospital 36.9 ± 48.0 32.1 ± 53.6 .650
Respiratory system diagnosis with ventilator support <96 hours (208) n = 39 n = 39
Mechanical ventilation 5.6 ± 5.3 3.7 ± 1.1 .032
ICU 4.8 ± 3.0 3.5 ± 1.9 .024
Hospital 9.3 ± 8.3 7.7 ± 4.8 .321
Major small and large bowel procedure with major complication or
comorbidity (329) n = 35 n = 35
Mechanical ventilation 11.7 ± 6.8 9.0 ± 11.2 .224
ICU 16.9 ± 9.4 13.2 ± 11.9 .155
Hospital 25.9 ± 12.6 22.3 ± 16.4 .315
ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; MS-DRG, Medicare
Severity diagnosis-related group; OR, operating room procedure; SD, standard deviation; VAP,
ventilator-associated pneumonia.
a
In general, there were few statistically significant differences between patients with and without
VAP in the seven MS-DRG categories. Specifically, there were no differences in patient or
hospital characteristics for the populations with MS-DRG 3: trach w/ MV ≥96 h with major OR,
MS-DRG 4: trach w/ MV ≥96 h without major OR, MS-DRG 870: sepsis w/ MV ≥96 h, and
MS-DRG 329: bowel procedure with major complication. The population with MS-DRG 207:
respiratory diagnosis w/ MV ≥96 h had higher rates of transfer to rehabilitation or skilled nursing
facilities than patients without VAP; they had lower rates of being discharged to home or
mortality. The population with MS-DRG 208: respiratory diagnosis w/ MV <96 h was generally
analogous except that patients with VAP had higher admission rates from other health facilities
and lower admission rates through the emergency room or physician referrals as well as lower
transfer rates to another hospital. Also in the population with MS-DRG 208: respiratory
diagnosis w/ MV <96 h, patients with VAP were more likely to be males than patients without
VAP (59.0% vs 35.9%). In the population with MS-DRG 853: infection w/ OR and major
complication, the VAP population had a higher mortality rate (41.3% vs 15.2%) and lower rates
of discharge to home, hospice, skilled nursing facility, or rehabilitation facility. The VAP
population was more heavily concentrated in the northeast
(23.9% vs 4.4%) and less
concentrated in the south (26.1% vs 52.2%; data not shown).
Online Table 2. Costs in a matched cohort of patients with VAP and patients without VAP MS-DRG (Code)
Outcome Type
Mean Cost ($) ± SDa
P With VAP Without VAP
ECMO or tracheostomy with mechanical ventilation ≥96 hours or principal diagnosis except face, mouth, and neck with major OR (3) Hospitalization 153,625 ± 105,696 142,827 ± 125,400 .113 Nursing time 5125 ± 25,149 7463 ± 23,720 .262 Pharmacy 21,318 ± 18,962 19,544 ± 27,124 .197 Antibiotic 2677 ± 5911 2442 ± 7138 .556 Vancomycin 425 ± 576 403 ± 537 .551
Propofol for sedation 953 ± 1699 806 ± 1558 .161
Ventilator 6653 ± 7535 5789 ± 6055 .032
Ventilator in ICU 5413 ± 5098 4900 ± 5029 .086
Respiratory therapy 3606 ± 5124 3292 ± 7653 .428
Chest x-rays 2620 ± 1858 2342 ± 1968 .013
Tracheostomy with mechanical ventilation ≥96 hours or principal diagnosis except face, mouth, and neck without major OR (4) Hospitalization 112,865 ± 77,784 83,187 ± 44,590 <.001 Nursing time 3296 ± 15,627 6285 ± 18,615 .201 Pharmacy 17,995 ± 19,811 12,669 ± 11,335 <.001 Antibiotic 2443 ± 3634 1700 ± 4273 .068 Vancomycin 393 ± 648 318 ± 409 .231
Propofol for sedation 1177 ± 1799 867 ± 1205 .071
Ventilator 6813 ± 7808 4322 ± 3293 <.001
Ventilator in ICU 5269 ± 6540 3576 ± 2753 <.001
Respiratory therapy 3619 ± 3885 2373 ± 2359 <.001
Chest x-rays 2274 ± 1648 1624 ± 1150 <.001
Respiratory system diagnosis with ventilator support ≥96 hours (207)
Hospitalization 46,928 ± 34,145 41,627 ± 24,701 .060
Nursing time 2211 ± 8474 1333 ± 5446 .339
Pharmacy 6312 ± 5679 5500 ± 4607 .096
Antibiotic 1081 ± 1172 736 ± 1050 .002
Vancomycin 217 ± 280 203 ± 269 .663
Propofol for sedation 980 ± 1630 650 ± 974 .051
Ventilator 3186 ± 3230 2450 ± 2883 .011
Online Table 2. Costs in a matched cohort of patients with VAP and patients without VAP MS-DRG (Code)
Outcome Type
Mean Cost ($) ± SDa
P With VAP Without VAP
Respiratory therapy 1583 ± 1726 1393 ± 1209 .194
Chest x-rays 954 ± 873 895 ± 647 .414
Septicemia or severe sepsis with mechanical ventilation ≥96 hours (870)
Hospitalization 59,238 ± 58,111 44,642 ± 25,851 .005
Nursing time 3275 ± 12,691 898 ± 2640 .100
Pharmacy 9523 ± 10,724 7468 ± 6671 .043
Antibiotic 1738 ± 2622 1025 ± 1023 .002
Vancomycin 251 ± 328 210 ± 278 .291
Propofol for sedation 819 ± 1868 544 ± 638 .209
Ventilator 3236 ± 4169 2017 ± 1817 <.001
Ventilator in ICU 2351 ± 2592 1862 ± 1728 .052
Respiratory therapy 2107 ± 3366 1251 ± 1385 .005
Chest x-rays 987 ± 798 792 ± 561 .013
Infectious and parasitic diseases with OR with major complication or comorbidity (853)
Hospitalization 103,082 ± 91,291 66,972 ± 51,444 .022
Nursing time 300 ± 454 3808 ± 9169 .104
Pharmacy 15,650 ± 17,692 10,399 ± 7642 .069
Antibiotic 2891 ± 4818 1703 ± 2046 .146
Vancomycin 332 ± 396 443 ± 835 .467
Propofol for sedation 1177 ± 3406 382 ± 547 .198
Ventilator 5176 ± 6789 1749 ± 1467 .001
Ventilator in ICU 2783 ± 2673 1503 ± 1074 .004
Respiratory therapy 3693 ± 4875 1272 ± 1651 .003
Chest x-rays 1713 ± 2055 956 ± 623 .019
Respiratory system diagnosis with ventilator support <96 hours (208)
Hospitalization 25,612 ± 20,324 17,593 ± 8269 .027
Nursing time 215 ± 417 708 ± 1859 .341
Pharmacy 2747 ± 1914 2137 ± 1306 .107
Antibiotic 545 ± 590 238 ± 185 .006
Vancomycin 151 ± 199 95 ± 115 .405
Propofol for sedation 237 ± 295 219 ± 264 .842
Ventilator 1240 ± 1092 789 ± 551 .025
Online Table 2. Costs in a matched cohort of patients with VAP and patients without VAP MS-DRG (Code)
Outcome Type
Mean Cost ($) ± SDa
P With VAP Without VAP
Respiratory therapy 824 ± 1333 569 ± 477 .290
Chest x-rays 579 ± 484 454 ± 263 .163
Major small and large bowel procedure with major complication or comorbidity (329)
Hospitalization 90,799 ± 62,532 69,767 ± 77,229 .215
Nursing time 4237 ± 14656 918 ± 2318 .323
Pharmacy 20,441 ± 47,013 12,976 ± 22,713 .401
Antibiotic 1794 ± 1898 1199 ± 1531 .163
Vancomycin 352 ± 535 174 ± 256 .196
Propofol for sedation 708 ± 925 413 ± 713 .210
Ventilator 2518 ± 1956 2258 ± 3418 .697
Ventilator in ICU 2457 ± 1961 2146 ± 3333 .635
Respiratory therapy 2038 ± 1575 1312 ± 1333 .057
Chest x-rays 1414 ± 908 1143 ± 1264 .306